Business
Seres Therapeutics Appoints Terri Young, Ph.D., R.Ph., Experienced Commercial Leader, as Executive Vice President, Chief Commercial and Strategy Officer
– Dr. Young to strengthen commercial expertise ahead of SER-109 Phase 3 data readout, and to maximize the potential of Seres’ microbiome therapeutic pipeline
About this update from Seres Therapeutics, Inc.
[{"type":"text","content":"\n– Dr. Young to strengthen commercial expertise ahead of SER-109 Phase 3 data readout, and to maximize the potential of Seres’ microbiome therapeutic pipeline –\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nSeres Therapeutics, Inc. (Nasdaq: MCRB) today announced the appointment of Terri Young, Ph.D., R.Ph., as Executive Vice President, Chief Commercial and Strategy Officer, effective June 29, 2020. Dr. Young brings to Seres over 20 years of commercial and marketing leadership experience, having successfully led the growth of several important biopharmaceutical products.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200622005155/en/Terri Young, Ph.D., R.Ph. (Photo: Business Wire)\n\n“We are thrilled to welcome Terri to the Seres team ahead of our anticipated, potentially pivotal SER-109 ECOSPOR III Phase 3 study readout in patients with recurrent C. difficile infection. Terri’s extensive marketing and sales leadership experience will be invaluable as we continue to prepare for the potential commercialization of SER-109,” said Eric Shaff, President and Chief Executive Officer of Seres. “In addition to SER-109, Terri will support the advancement of our overall microbiome therapeutic pipeline targeting infectious diseases, immunological conditions and cancer. In particular, we look forward to Terri’s contributions on our promising SER-287 program, which is in a Phase 2b study for ulcerative colitis.”\n\n\n“I am excited to join Seres as the Company prepares for the potential commercialization of SER-109. Recurrent C. difficile is a condition where improved treatment options are urgently needed, and SER-109 has the potential to fundamentally transform how patients are managed,” said Dr. Young. “In addition to SER-109, Seres is advancing an innovative pipeline of microbiome therapeutic candidates, including SER-287 and SER-301 for ulcerative colitis and SER-401 and SER-155 for cancer. I look forward to working with the team to implement strategies that maximize the enormous potential of this novel therapeutic modality.”\n\n\nPrior to joining Seres, Dr. Young served as Vice President, Global Commercial Strategy at Sage Therapeutics, where she led development of Sage’s global commercial capabilities, including global marketing, insights and analytics and new product planning. Pr...